New quadrivalent flu vaccine shows promise in large chinese trial
NCT ID NCT04210349
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 3 study tested a quadrivalent (four-strain) influenza vaccine against two trivalent (three-strain) vaccines in over 7,100 Chinese participants aged 6 months and older. The goal was to see if the quadrivalent vaccine triggers a stronger immune response and provides broader protection. Researchers also monitored safety, including injection site reactions and serious adverse events.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Quadrivalent inactivated influenza vaccine
What this could lead to
If successful, this vaccine could provide broader protection against influenza by covering four virus strains instead of three.
What could go wrong
This is a completed phase 3 trial, so results are mature, but the vaccine is specific to strains circulating in China and may not generalize globally. Safety and efficacy data are still limited to this population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number 1561000
Kunming, 650022, China
-
Investigational Site Number 1561001
Lincang, 677001, China
-
Investigational Site Number 1561002
Lincang, 677001, China
-
Investigational Site Number 1561003
Lincang, 677001, China
-
Investigational Site Number 1562000
Zhengzhou, 450002, China
-
Investigational Site Number 1562001
Shangqiu, 476000, China
-
Investigational Site Number 1562002
Xinxiang, 453200, China